General Surgery, Basaksehir State Hospital, Istanbul 34230, Turkey.
Anticancer Res. 2010 Jul;30(7):3093-8.
Previous studies have shown alterations in the cell cycle regulatory proteins in breast carcinomas. However, the results of these studies remain controversial. Cyclin D1 (CCND1) and p27(KIP1) (CDKN1B) are two essential regulators of cell cycle progression. This study aimed to investigate the associations of CCND1 A870G and CDKN1B C79T polymorphisms with breast cancer risk.
Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to determine the genotype and allelic frequencies of polymorphisms. Seventy-eight breast cancer patients and 84 age-matched healthy controls were included in the study.
Frequencies of CT genotype and T allele of CDKN1B were found to be higher in breast cancer patients than in controls (p=0.013, OR: 1.514 95% CI: 1.086-2.114.15; p=0.007, OR=1.496; 95% CI: 1.111-2.014, respectively). The frequency of AA genotype of CCND1 was decreased in hormone receptor- (estrogen and progesterone receptors) negative patients with breast cancer (p<0.049, OR=0.286; 95% CI: 0.071-1.142)
Even though CDKN1B polymorphism appears to be an important predictive factor for breast cancer risk and CCND1 polymorphism may be a prognostic biomarker for breast cancer, further investigations with larger study groups are needed to fully elucidate the role of CCND1 and CDKN1B polymorphisms in the development and prognosis of breast cancer.
先前的研究表明乳腺癌中细胞周期调控蛋白发生改变。然而，这些研究的结果仍存在争议。细胞周期蛋白 D1（CCND1）和 p27（KIP1）（CDKN1B）是细胞周期进程的两个重要调节因子。本研究旨在探讨 CCND1 A870G 和 CDKN1B C79T 多态性与乳腺癌风险的相关性。
采用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）检测多态性的基因型和等位基因频率。将 78 例乳腺癌患者和 84 名年龄匹配的健康对照纳入研究。
CDKN1B 的 CT 基因型和 T 等位基因频率在乳腺癌患者中高于对照组（p=0.013，OR：1.514 95%CI：1.086-2.114；p=0.007，OR=1.496；95%CI：1.111-2.014）。激素受体阴性（雌激素和孕激素受体）乳腺癌患者 CCND1 的 AA 基因型频率降低（p<0.049，OR=0.286；95%CI：0.071-1.142）。
尽管 CDKN1B 多态性似乎是乳腺癌风险的重要预测因子，CCND1 多态性可能是乳腺癌的预后生物标志物，但需要进一步进行更大的研究组来充分阐明 CCND1 和 CDKN1B 多态性在乳腺癌发生和预后中的作用。
